A contentious, United States-funded clinical trial involving newborns in Guinea-Bissau has been halted following mounting concerns over bioethics, coercive consent and the dangers of deliberately withholding a proven vaccine from infants.

According to the University of Washington, the study, led by Danish researchers from the Bandim Health Project, was slated to receive $1.6 million from the U.S. Centers for Disease Control and Prevention (CDC) alongside matching funds from private philanthropies. Its stated objective was to investigate whether the hepatitis B vaccine yields “non-specific” health benefits beyond preventing liver infection – such as impacts on overall mortality, skin conditions and early neurodevelopment.

However, the trial’s experimental design required half of its 14,000 enrolled newborns to wait six weeks before receiving their first hepatitis B dose, while the other half received it at birth. That structural delay quickly drew condemnation from pediatricians, bioethicists and local authorities who saw the protocol as an unjustifiable departure from standard medical care.

What we know about the halted African vaccine trial

The controversy in Guinea-Bissau does not stem from vaccine skepticism or an unapproved pharmaceutical product. The hepatitis B vaccine is a proven, globally recognized immunization that has safely prevented chronic disease and death for decades.

Hepatitis B is a viral infection that attacks the liver, often transmitted vertically from mother to infant during delivery. When contracted at birth, the infection becomes chronic in up to 90% of cases, putting infants at high risk for cirrhosis, liver failure and liver cancer later in life. Because of this window of vulnerability, the World Health Organization (WHO) explicitly advises that every newborn receive their first dose of the hepatitis B vaccine as soon as possible after birth – ideally within the first 24 hours.

The Bandim Health Project’s researchers hypothesized that co-administering vaccines or altering their timing might alter non-specific immune responses, citing historical observations surrounding live vaccines like BCG. Yet by designing a study where thousands of infants were randomized into a six-week waiting period, the researchers knowingly compromised standard protection against a chronic, preventable pathogen in order to chase an unproven secondary theory.

Understanding the double standard

Beyond the pharmacological risks, the trial exposes the persistent ethical double standard between clinical research conducted in Western nations and studies carried out in the Global South. A trial deliberately withholding an established birth-dose vaccine from infants would face immediate rejection from Institutional Review Boards in the United States or Denmark.

The study’s consent model also raised immediate alarms. In Guinea-Bissau, systemic resource constraints mean that routine hepatitis B birth doses are not yet universally accessible across all public maternity wards. Researchers effectively established an environment where participating in the study was the only way a parent could secure an immediate birth dose for their child. Those who consented were placed into a 50/50 lottery to receive the shot; those who opted out were guaranteed to receive nothing at birth. Bioethicists argue that dangling a standard-of-care immunization under the guise of an experimental trial invalidates true informed consent.

The fallout reached a boiling point when Guinea-Bissau’s Minister of Health, Quinhin Nantote, publicly stated that the national government had never approved the trial in its proposed format. Authorities subsequently launched an inquiry into the project’s local offices and seized the hepatitis B vaccines being held by the research team.

On Oct. 21, lead researcher Frederik Schaltz-Buchholzer conceded that the trial would not move forward in Guinea-Bissau without government clearance. The intervention by health authorities marks a significant assertion of medical sovereignty, signaling that international research initiatives cannot bypass local regulatory authority or trade the baseline safety of African children for theoretical Western inquiries.

The science behind the HepB birth dose

Hepatitis B is a viral infection that attacks the liver, spread primarily through exposure to infected blood and bodily fluids. While adults frequently clear the virus without long-term complications, the infection carries devastating stakes for newborns infected during childbirth.

When an infant contracts hepatitis B at birth, their developing immune system cannot effectively mount a defense. Up to 90% of infected newborns go on to develop chronic infection – a silent, progressive condition that often goes undetected for decades before manifesting as cirrhosis, liver failure or liver cancer later in life.

Because vertical transmission during delivery carries such severe long-term consequences, immediate immunization is the medical standard worldwide.

“The hepatitis B vaccine stimulates the immune system to produce antibodies to a protein closely related to that of the hepatitis B virus. This enables the body to build durable immunity without actually contracting the disease,” explains Dr. Justus Rabach, a clinical physician and surgeon. “The World Health Organization (WHO) explicitly recommends administering the birth dose within 24 hours of delivery, followed by subsequent doses to complete the series. Vaccines have a long track record of safety and are deemed both safe and effective by global public health authorities.”

Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, was unequivocal in his critique of the study’s protocol. “The solution is clear here,” Dr. Offit stated. “Take the money and vaccinate as many kids as you can.”

Dr. Offit’s stance captures the fundamental ethical consensus across global health: international funding and clinical resources must focus on expanding direct access to proven, life-saving interventions, rather than underwriting trials that intentionally withhold them to test unconfirmed hypotheses.

Why safety is a concern

The controversy surrounding the halted Guinea-Bissau trial is fundamentally a critique of experimental design, not vaccine safety. The efficacy and safety profile of the hepatitis B vaccine itself are settled science, reinforced by decades of clinical outcomes across millions of children. The danger lay entirely in the researchers’ decision to leave thousands of infants unprotected for the first six weeks of life.

Researchers attempted to defend the delay by proposing to screen mothers and exclude infants born to those who tested positive for hepatitis B. However, rapid diagnostic tests do not offer 100% sensitivity. A single false-negative maternal screen would leave an infant exposed to perinatal infection without the prophylactic barrier of an immediate birth dose. Furthermore, newborns remain vulnerable to horizontal transmission from family members and close caregivers in the weeks following delivery.

Beyond the clinical risks, the study created conditions of structural coercion. True informed consent requires that parents understand the risks, benefits and alternatives without being forced into an untenable compromise. In resource-limited environments where public health systems do not yet provide universal access to the hepatitis B birth dose, conditioning access to standard medical care on trial enrollment strips parents of genuine autonomy. When enrollment becomes the only viable path to securing early protection, consent ceases to be voluntary.

Protecting pediatric welfare requires uncompromised adherence to international ethical standards and domestic legal oversight. Approval from foreign ethics boards or Western academic institutions does not supersede the regulatory authority of the sovereign nation where the research takes place.

Ultimately, public pushback against an unethical trial does not mean the vaccine is dangerous or that scientific inquiry should cease. Instead, it reaffirms an essential boundary in global health: scientific curiosity can never justify stripping vulnerable populations of established standards of care.

Risks and side effects

Like any routine childhood immunization, the hepatitis B shot prompts the body to build durable antibodies – a process that can trigger mild, temporary physical responses. The Mayo Clinic states that for most infants and children, the injection produces no noticeable reaction. When side effects do occur, they are typically low-grade immune responses that resolve naturally within 24 to 48 hours, including:

  • Local tenderness, minor swelling, or temporary redness at the injection site.
  • Low-grade fever.
  • Mild fatigue, temporary fussiness, or short-lived irritability in infants.

These minor symptoms are signs of a responsive immune system learning to protect itself, not indications of illness or chronic damage. In contrast, severe systemic allergic reactions such as anaphylaxis are exceptionally rare, occurring at an estimated rate of roughly one in 1.1 million doses. Clinical staff are trained to recognize and treat these immediate reactions, which present with symptoms such as difficulty breathing, swelling of the face or throat, widespread hives or sudden weakness.

When weighing potential side effects, it is essential to ground decisions in the actual dangers of the infection itself. Hepatitis B contracted perinatally becomes a chronic, lifelong disease in up to 90% of infants, often silently driving liver cirrhosis and liver cancer later in life. Decades of global clinical surveillance across millions of infants have repeatedly confirmed that the hepatitis B vaccine carries an exceptional safety profile and bears no link or correlation to autism.

It is completely natural to research what goes into your newborn’s body, especially when navigating a healthcare system that historically has not always listened to Black parents or validated maternal instincts. If you come across alarming claims or conflicting advice, bring those specific questions directly to your pediatrician. A provider who values health equity will take the time to walk you through the data, address your concerns with transparency and collaborate with you on your child’s care without dismissing your vigilance.

Who should not get the HepB vaccine?

The hepatitis B vaccine is recommended as part of the schedule for most newborns, children and adults.

Individuals who have experienced a severe allergic reaction to a previous dose of hepatitis B vaccine or to any of the vaccine’s components may not take the vaccine or may require specialist advice. Some vaccine preparations contain yeast-based additives, and this is important for those individuals with serious allergies.

Appropriate vaccine and timing should be decided by a healthcare professional after reviewing the person’s medical history. Also, moderate or severe acute illness may impact the timing of vaccination.

The birth dose is especially crucial for newborns if their mother is infected with hepatitis B or the infection status is unknown. Parents should not delay a recommended dose without seeking advice from a healthcare professional.

Best practices

To best protect newborns in Guinea-Bissau, strengthening the uptake of recommended hepatitis B vaccination is most likely to have a direct impact.

Practical measures include:

  • Provide the birth dose promptly: Aim to vaccinate newborns within 24 hours, in line with WHO guidance.
  • Complete the vaccine series: Ensure babies receive the additional doses needed for protection.
  • Test pregnant women: Identify maternal hepatitis B infection and provide appropriate care to reduce transmission.
  • Support informed decisions: Explain vaccine benefits, possible side effects and the risks of infection in clear language.
  • Strengthen local healthcare systems: Fund vaccine supplies, trained healthcare workers and reliable follow-up services.
  • Require transparent research approval: Ensure proposed studies receive valid national authorization and independent ethical review before enrollment begins.

WHO has voiced support for assisting the country of Guinea-Bissau in the introduction of universal hepatitis B vaccination at birth. A broader birth-dose program is planned for 2028 for the country.

The study of wider vaccine effects can proceed as long as it is scientifically warranted, but not at the expense of denying protection to the vulnerable children.

Bottom line

The hepatitis B vaccine trial in Guinea-Bissau, which has been supported by the United States, was suspended following disagreements over the government’s approval and serious ethical issues. It is not evidence of the hepatitis B vaccine’s safety that is in dispute; it is the proposed study design. Timely vaccination is still an effective public health intervention to protect newborns.

Frequently Asked Questions

How often do you need the hepatitis B vaccine?

Most people need a complete series of two or three doses, depending on the vaccine used and their age; healthy people generally do not need routine boosters after completing the recommended series.

Is hepatitis B 100% curable?

No, chronic hepatitis B does not currently have a reliable cure, although antiviral medicines can control the infection and reduce the risk of serious liver damage. Acute hepatitis B often resolves without specific treatment in adults, but medical monitoring may be necessary.

Citations

WHO. Hepatitis B. World Health Organization. April 9, 2024. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

University of Washington. The CDC is Funding an Unethical Vaccine Trial in Guinea-Bissau. Global Health Justice. December 24, 2025. https://depts.washington.edu/globalhealthjustice/the-cdc-is-funding-an-unethical-vaccine-trial-in-guinea-bissau/

Hepatitis B Foundation. What is Hepatitis B? Hepb.org. 2019. https://www.hepb.org/what-is-hepatitis-b/what-is-hepb/

Mayo Clinic. Hepatitis B – Symptoms and Causes. Mayo Clinic. October 4, 2024. https://www.mayoclinic.org/diseases-conditions/hepatitis-b/symptoms-causes/syc-20366802

WHO. Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau. WHO.int. 2026. https://www.who.int/news/item/13-02-2026-statement-on-the-planned-hepatitis-b-birth-dose-vaccine-trial-in-guinea-bissau